Inflammatory bowel diseases (IBD) are complex and multifactorial diseases that require a differentiated and evolving treatment approach. When monotherapies reach their limits, the need for combination strategies grows. The focus is on both conventional combination regimens and innovative applications of dual biological (targeted) therapies.
Partner
Autoren
- PD Dr. med. Pascal Juillerat
- Prof. Dr. med. Stephan Brand
Publikation
- GASTROENTEROLOGIE PRAXIS
Related Topics
You May Also Like
- Microbiome, inflammaging and affective/cognitive health
Gut-brain axis in old age
- Vitiligo - the level of suffering should not be underestimated
A lot can be achieved therapeutically nowadays
- Patient-centered rounds in medicine
Aligning care with the patient
- Adrenogenital syndrome
Clinical care from birth to adulthood
- Communication between hospitals and outpatient care
How does a digital clinical information system prove itself in everyday practice?
- Acute myeloid leukemia
Treatment decisions between MRD monitoring, transplantation and CAR-T cells
- Psoriasis and metabolic comorbidities: new study data
GLP-1RAs showed a valuable dual benefit
- Heart failure: combination of four as "Guideline-Directed Medical Therapy"